Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1997 Jan;6(1):132–140. doi: 10.1002/pro.5560060115

Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va.

A J Gale 1, X Sun 1, M J Heeb 1, J H Griffin 1
PMCID: PMC2143509  PMID: 9007985

Abstract

The human plasma serine protease, activated protein C (APC), primarily exerts its anticoagulant function by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa. A recombinant active site Ser 360 to Ala mutation of protein C was prepared, and the mutant protein was expressed in human 293 kidney cells and purified. The activation peptide of the mutant protein C zymogen was cleaved by a snake venom activator, Protac C, but the "activated" S360A APC did not have amidolytic activity. However, it did exhibit significant anticoagulant activity both in clotting assays and in a purified protein assay system that measured prothrombinase activity. The S360A APC was compared to plasma-derived and wild-type recombinant APC. The anticoagulant activity of the mutant, but not native APC, was resistant to diisopropyl fluorophosphate, whereas all APCs were inhibited by monoclonal antibodies against APC. In contrast to native APC, S360A APC was not inactivated by serine protease inhibitors in plasma and did not bind to the highly reactive mutant protease inhibitor M358R alpha 1 antitrypsin. Since plasma serpins provide the major mechanism for inactivating APC in vivo, this suggests that S360A APC would have a long half-life in vivo, with potential therapeutic advantages. S360A APC rapidly inhibited factor Va in a nonenzymatic manner since it apparently did not proteolyze factor Va. These data suggest that native APC may exhibit rapid nonenzymatic anticoagulant activity followed by enzymatic irreversible proteolysis of factor Va. The results of clotting assays and prothrombinase assays showed that S360A APC could not inhibit the variant Gln 506-FVa compared with normal Arg 506-FVa, suggesting that the active site of S360A APC binds to FVa at or near Arg 506.

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birktoft J. J., Blow D. M. Structure of crystalline -chymotrypsin. V. The atomic structure of tosyl- -chymotrypsin at 2 A resolution. J Mol Biol. 1972 Jul 21;68(2):187–240. doi: 10.1016/0022-2836(72)90210-0. [DOI] [PubMed] [Google Scholar]
  2. Branson H. E., Katz J., Marble R., Griffin J. H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983 Nov 19;2(8360):1165–1168. doi: 10.1016/s0140-6736(83)91216-3. [DOI] [PubMed] [Google Scholar]
  3. Carter P., Wells J. A. Dissecting the catalytic triad of a serine protease. Nature. 1988 Apr 7;332(6164):564–568. doi: 10.1038/332564a0. [DOI] [PubMed] [Google Scholar]
  4. Conard J., Bauer K. A., Gruber A., Griffin J. H., Schwarz H. P., Horellou M. H., Samama M. M., Rosenberg R. D. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15;82(4):1159–1164. [PubMed] [Google Scholar]
  5. Dreyfus M., Magny J. F., Bridey F., Schwarz H. P., Planché C., Dehan M., Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991 Nov 28;325(22):1565–1568. doi: 10.1056/NEJM199111283252207. [DOI] [PubMed] [Google Scholar]
  6. Dreyfus M., Masterson M., David M., Rivard G. E., Müller F. M., Kreuz W., Beeg T., Minford A., Allgrove J., Cohen J. D. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995;21(4):371–381. doi: 10.1055/s-2007-1000658. [DOI] [PubMed] [Google Scholar]
  7. Esmon C. T., Owen W. G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2249–2252. doi: 10.1073/pnas.78.4.2249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Esmon C. T., Taylor F. B., Jr, Snow T. R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost. 1991 Jul 12;66(1):160–165. [PubMed] [Google Scholar]
  9. Fay P. J., Beattie T., Huggins C. F., Regan L. M. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994 Aug 12;269(32):20522–20527. [PubMed] [Google Scholar]
  10. Fehlhammer H., Bode W., Huber R. Crystal structure of bovine trypsinogen at 1-8 A resolution. II. Crystallographic refinement, refined crystal structure and comparison with bovine trypsin. J Mol Biol. 1977 Apr 25;111(4):415–438. doi: 10.1016/s0022-2836(77)80062-4. [DOI] [PubMed] [Google Scholar]
  11. Grey S. T., Tsuchida A., Hau H., Orthner C. L., Salem H. H., Hancock W. W. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 1994 Oct 15;153(8):3664–3672. [PubMed] [Google Scholar]
  12. Gruber A., Griffin J. H. Direct detection of activated protein C in blood from human subjects. Blood. 1992 May 1;79(9):2340–2348. [PubMed] [Google Scholar]
  13. Heeb M. J., Bischoff R., Courtney M., Griffin J. H. Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. J Biol Chem. 1990 Feb 5;265(4):2365–2369. [PubMed] [Google Scholar]
  14. Heeb M. J., Griffin J. H. Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem. 1988 Aug 25;263(24):11613–11616. [PubMed] [Google Scholar]
  15. Heeb M. J., Kojima Y., Greengard J. S., Griffin J. H. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995 Jun 15;85(12):3405–3411. [PubMed] [Google Scholar]
  16. Heeb M. J., Kojima Y., Hackeng T. M., Griffin J. H. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci. 1996 Sep;5(9):1883–1889. doi: 10.1002/pro.5560050914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Heeb M. J., Mesters R. M., Tans G., Rosing J., Griffin J. H. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem. 1993 Feb 5;268(4):2872–2877. [PubMed] [Google Scholar]
  18. Heeb M. J., Schwarz H. P., White T., Lämmle B., Berrettini M., Griffin J. H. Immunoblotting studies of the molecular forms of protein C in plasma. Thromb Res. 1988 Oct 1;52(1):33–43. doi: 10.1016/0049-3848(88)90038-2. [DOI] [PubMed] [Google Scholar]
  19. Kalafatis M., Mann K. G. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem. 1993 Dec 25;268(36):27246–27257. [PubMed] [Google Scholar]
  20. Kalafatis M., Rand M. D., Mann K. G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994 Dec 16;269(50):31869–31880. [PubMed] [Google Scholar]
  21. Kisiel W., Canfield W. M., Ericsson L. H., Davie E. W. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry. 1977 Dec 27;16(26):5824–5831. doi: 10.1021/bi00645a029. [DOI] [PubMed] [Google Scholar]
  22. Kisiel W. Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest. 1979 Sep;64(3):761–769. doi: 10.1172/JCI109521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kossiakoff A. A., Chambers J. L., Kay L. M., Stroud R. M. Structure of bovine trypsinogen at 1.9 A resolution. Biochemistry. 1977 Feb 22;16(4):654–664. doi: 10.1021/bi00623a016. [DOI] [PubMed] [Google Scholar]
  24. Kraut J. Serine proteases: structure and mechanism of catalysis. Annu Rev Biochem. 1977;46:331–358. doi: 10.1146/annurev.bi.46.070177.001555. [DOI] [PubMed] [Google Scholar]
  25. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  26. Liao D. I., Remington S. J. Structure of wheat serine carboxypeptidase II at 3.5-A resolution. A new class of serine proteinase. J Biol Chem. 1990 Apr 25;265(12):6528–6531. doi: 10.2210/pdb2sc2/pdb. [DOI] [PubMed] [Google Scholar]
  27. Marlar R. A., Kleiss A. J., Griffin J. H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982 May;59(5):1067–1072. [PubMed] [Google Scholar]
  28. Mesters R. M., Houghten R. A., Griffin J. H. Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity. J Biol Chem. 1991 Dec 25;266(36):24514–24519. [PubMed] [Google Scholar]
  29. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996 Jan 15;87(2):642–647. [PubMed] [Google Scholar]
  30. O'Brien L. M., Medved L. V., Fay P. J. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem. 1995 Nov 10;270(45):27087–27092. doi: 10.1074/jbc.270.45.27087. [DOI] [PubMed] [Google Scholar]
  31. Okajima K., Koga S., Kaji M., Inoue M., Nakagaki T., Funatsu A., Okabe H., Takatsuki K., Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990 Feb 19;63(1):48–53. [PubMed] [Google Scholar]
  32. Pan Y., DeFay T., Gitschier J., Cohen F. E. Proposed structure of the A domains of factor VIII by homology modelling. Nat Struct Biol. 1995 Sep;2(9):740–744. doi: 10.1038/nsb0995-740. [DOI] [PubMed] [Google Scholar]
  33. Pichler L., Schramm W., Ulrich W., Varadi K., Schwarz H. P. Antinociceptive properties of protein C in a model of inflammatory hyperalgesia in rats. Thromb Haemost. 1995 Feb;73(2):252–255. [PubMed] [Google Scholar]
  34. Richardson M. A., Gerlitz B., Grinnell B. W. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant. Nature. 1992 Nov 19;360(6401):261–264. doi: 10.1038/360261a0. [DOI] [PubMed] [Google Scholar]
  35. Rivard G. E., David M., Farrell C., Schwarz H. P. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995 Apr;126(4):646–652. doi: 10.1016/s0022-3476(95)70369-1. [DOI] [PubMed] [Google Scholar]
  36. Schramm W., Spannagl M., Bauer K. A., Rosenberg R. D., Birkner B., Linnau Y., Schwarz H. P. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun;129(6):753–756. [PubMed] [Google Scholar]
  37. Snow T. R., Deal M. T., Dickey D. T., Esmon C. T. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation. 1991 Jul;84(1):293–299. doi: 10.1161/01.cir.84.1.293. [DOI] [PubMed] [Google Scholar]
  38. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem. 1976 Jan 25;251(2):355–363. [PubMed] [Google Scholar]
  39. Stroud R. M., Kay L. M., Dickerson R. E. The structure of bovine trypsin: electron density maps of the inhibited enzyme at 5 Angstrom and at 2-7 Angstron resolution. J Mol Biol. 1974 Feb 25;83(2):185–208. doi: 10.1016/0022-2836(74)90387-8. [DOI] [PubMed] [Google Scholar]
  40. Walker F. J., Sexton P. W., Esmon C. T. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta. 1979 Dec 7;571(2):333–342. doi: 10.1016/0005-2744(79)90103-7. [DOI] [PubMed] [Google Scholar]
  41. Wang D., Bode W., Huber R. Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 A resolution. J Mol Biol. 1985 Oct 5;185(3):595–624. doi: 10.1016/0022-2836(85)90074-9. [DOI] [PubMed] [Google Scholar]
  42. Zhang L., Castellino F. J. A gamma-carboxyglutamic acid (gamma) variant (gamma 6D, gamma 7D) of human activated protein C displays greatly reduced activity as an anticoagulant. Biochemistry. 1990 Dec 4;29(48):10828–10834. doi: 10.1021/bi00500a016. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES